Results 61 to 70 of about 10,856 (192)
A phenomap of TTR amyloidosis to aid diagnostic screening
ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos +4 more
wiley +1 more source
Amyloïdose héréditaire à transthyrétine [Transthyretin-related hereditary amyloidosis]
, 2016 Transthyretin-related hereditary amyloidosis (ATTR) is a progressive and potentially lethal genetic disorder, transmitted as an autosomal dominant trait. Tissue injury is induced by amyloid fibrils consisting of mutated transthyretin.
Moradpour, D. +4 more
core +1 more source
Анналы клинической и экспериментальной неврологииHereditary transthyretin amyloidosis is a fatal systemic progressive disease caused by mutations in the transthyretin (TTR) gene, inherited in an autosomal dominant pattern, primarily affecting the peripheral and autonomic nervous systems and the heart ...
Elizaveta A. Guseva +2 more
doaj +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer +25 more
wiley +1 more source
ESC Heart FailureAims Recognition of transthyretin amyloid cardiomyopathy is increasing due to advances in cardiac imaging and diagnostic strategies, but questions remain regarding disease frequency and characteristics.
Pablo Garcia‐Pavia +10 more
doaj +1 more source
Autonomous Nanomedicine: Closing the Biological Validation Gap
Exploration, EarlyView.Delivery of nanoparticles to tumors has not improved in over fifteen years, and biological testing remains slow and separate from formulation design. This review proposes adding a Biology step to the design cycle, using organ chips and patient‐derived organoids, and assesses the readiness of each required technology.
Yan Jun Lin, Izabella Komperda
wiley +1 more source
, 2010 Transthyretin amyloid polyneuropathy, caused by mutations in the transthyretin gene, is a progressive condition for which liver transplantation is an established treatment.
Harley, H. +6 more
core +1 more source
iNew Medicine, EarlyView.ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid +4 more
wiley +1 more source
Human transthyretin (TTR) complexed with curcumin
, 2014 Human transthyretin (TTR) complexed with ...
Ciccone, L., Stura, E. A.
core +1 more source
Development of Benziodarone Analogues with Enhanced Potency for Selective Binding to Transthyretin in Human Plasma [PDF]
Transthyretin amyloidosis is a fatal disorder caused by transthyretin amyloid aggregation. Stabilizing the native structure of transthyretin is an effective approach to inhibit amyloid aggregation.
Kanako Fujii (18452968) +13 more
core +3 more sources